Abbott (ABT) – StreetInsider.com Reports
-
Abbott Labs (ABT) PT Lowered to $140 at Barclays
-
Citi Reiterates Buy Rating on Abbott Labs (ABT)
-
Abbott Labs (ABT) PT Lowered to $125 at RBC Capital
-
Midday movers: Travelers, JB Hunt fall; United Airlines rises
-
Abbott Laboratories (ABT) narrows 2024 earnings guidance, shares slip
-
Abbott's device sales drive profit beat, but shares fall as forecast disappoints
-
Abbott (ABT) Tops Q1 EPS by 2c, Offers Guidance
-
Abbott (ABT) April 109 straddle into quarter results
-
Abbott (ABT) April option implied volatility elevated into quarter results
-
Abbott Labs (ABT) PT Raised to $128 at Citi
-
Abbott (ABT) Receives FDA Approval for TriClip
-
Midday movers: Adobe, Zillow fall; Micron rises
-
Reckitt to challenge $60 million baby formula verdict, shares sink
-
Reckitt Drops 10% On Concern About Baby Formula Pay Out
-
Reckitt unit hit with $60 million verdict in Enfamil baby formula case in Illinois
-
Ancora Nominates Four Highly Qualified, Independent Director Candidates and Urges Orderly CEO Succession at Elanco Animal Health (ELAN)
-
Abbott (ABT) Declares $0.55 Quarterly Dividend; 1.9% Yield
-
Abbott (ABT) Announces FDA AdCom's Vote in in Favor of TriClip System
-
Abbott Labs (ABT) PT Raised to $141 at Barclays
-
Abbott (ABT) Launches World's Smallest Rechargeable System
-
Abbott Labs (ABT) PT Raised to $133 at Wells Fargo
-
Abbott Labs (ABT) PT Raised to $125 at JPMorgan
-
Abbott Labs (ABT) PT Raised to $126 at Citi
-
Midday movers: Netflix gains, ASML spurs rally in chip stocks
-
Abbott (ABT) slips as results, guidance barely meet consensus
-
Abbott forecasts 2024 earnings largely below estimates, shares down
-
Abbott (ABT) Reports In-Line Q4 EPS, Offers Guidance
-
Tesla to report, Netflix's strong subscriber sign-ups - what's moving markets
-
Abbott (ABT) January weekly option implied volatility into quarter results
-
Abbott (ABT) January weekly 115 straddle priced into quarter results
-
Dow Jones, Nasdaq, S&P 500 weekly preview: Are new highs sustainable?
-
Abbott Labs (ABT) PT Raised to $136 at UBS
-
Abbott Labs (ABT) PT Raised to $131 at Wells Fargo
-
Abbott Labs (ABT) PT Raised to $128 at RBC Capital
-
Abbott Labs (ABT) PT Raised to $135 at BTIG
-
Healthcare a contrarian idea into 2024 - these stocks could see upside
-
Analysts downplay Medicare cost-cutting impact on Dexcom as shares drop 5%
-
Abbott (ABT) Raises Quarterly Dividend 7.8% to $0.55; 2% Yield
-
Abbott Labs (ABT) PT Raised to $121 at Wells Fargo
-
Abbott Labs (ABT) PT Raised to $123 at Citi
-
Medical Devise Stocks Gain on Better Than Feared Wegovy Data
-
Abbott (ABT) Granted FDA Approval of HPV Test to Run on Alinity m
-
Abbott to cease sale of infant probiotic products after FDA warning
-
Here's why these are UBS' most preferred healthcare stocks
-
Medical device makers see limited hit from weight-loss drugs
-
Abbott Labs (ABT) PT Lowered to $107 at Morgan Stanley
-
Abbott Labs (ABT) PT Raised to $122 at UBS
-
Abbott Labs (ABT) PT Lowered to $110 at Raymond James
-
Abbott Labs (ABT) PT Raised to $133 at Barclays
-
Abbott Labs (ABT) PT Lowered to $115 at Stifel
Back to ABT Stock Lookup